# Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

> **NCT06647563** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 355 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** Toripalimab
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy 60 Gray/day
- **RADIATION:** Radiotherapy 66 Gray/day
- **RADIATION:** Radiotherapy 70 Gray/day

## Key facts

- **NCT ID:** NCT06647563
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 355 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647563, "Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06647563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*